Lentiviral vectors are being developed to satisfy a wide range of currently unmet medical needs. Vectors destined for clinical evaluation have been rendered multiply defective by deletion of all viral coding sequences and nonessential cis-acting sequences from the transfer genome. The viral envelope and accessory proteins are excluded from the production system. The vectors are produced from separate expression plasmids that are designed to minimize the potential for homologous recombination. These features ensure that the regeneration of the starting virus is impossible. It is a regulatory requirement to confirm the absence of any replication competent virus, so we describe here the development and validation of a replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based vectors. The assay is based on the guidelines developed for testing retroviral vectors, and uses the F-PERT (fluorescent-product enhanced reverse transcriptase) assay to test for the presence of a transmissible reverse transcriptase. We have empirically modelled the replication kinetics of an EIAV-like entity in human cells and devised an amplification protocol by comparison with a replication competent MLV. The RCL assay has been validated at the 20 litre manufacturing scale, during which no RCL was detected. The assay is theoretically applicable to any lentiviral vector and pseudotype combination.
Introduction
Lentiviral vectors derived from primate (HIV-1, HIV-2, SIV-1) and nonprimate (FIV, EIAV, BIV) viruses are promising delivery systems for gene therapy as they transduce nondividing cells such as neuronal, muscle or haematopoietic cells and maintain expression without shutdown. [1] [2] [3] We have developed vectors based on equine infectious anaemia virus (EIAV) intended for human clinical use to treat diseases including Parkinson's disease, 4 ,5 motor neuron disease 6 and spinal cord injury. 7 These vectors have been designed to maximize safety but it is also necessary to evaluate safety in appropriate assays. We now report the design and validation of an assay to detect the presence of replication competent lentivirus (RCL) in EIAV vector preparations.
A concern is that the original replication competent virus might be reconstructed from the components during production by site-specific recombination, or alternatively a novel virus might be generated by recombination of the vector components with endogenous virus-like elements. The latter is of particular concern where the starting virus is naturally tropic for the production cells, as was the case when murine retroviral vectors were produced in mouse cells resulting in replication competent retroviruses (RCRs). 8 Avoiding the use of the natural host cells for production leaves the major concern as recombination between the vector components or by nonhomologous recombination.
A number of unique features of lentiviral vectors dictate that the design of RCL assays be different from the classical assays developed for retroviral vectors. First, classical virological approaches, such as focus forming assays, 9 are not suitable due to the use of a variety of heterologous envelope glycoproteins to pseudotype retroviral [9] [10] [11] and lentiviral [12] [13] [14] [15] vectors. Secondly, the use of EIAV as a positive control virus is inappropriate because the cis-acting sequences and regulatory proteins required for natural replication are missing and because the vectors are so divergent from their parental virus: the only lentiviral gene present in the EIAV packaging system is codon-optimized Gag-Pol, and the components are separated onto different plasmids; together these features are aimed at minimizing the potential for recombination. 2, [16] [17] [18] [19] [20] Thirdly, it is essential to assay for RCL on a human cell line, which is compatible with the fact that it is particularly human cell tropism that is of interest for clinical safety. This is due to the trend to use human cell production systems for manufacturing and as these are often not the natural host cells for the parental virus, there would potentially be selection for novel human cell tropic entities. Finally, it is desirable to develop a generic assay rather than a product-specific assay so it does not rely upon the prediction of the genetic configuration of a replicating entity (RCL).
We now describe an RCL assay for EIAV based vectors that has generic features that could be adapted for any lentiviral vector. The assay uses reverse transcriptase (RT) as a surrogate marker for an RCL because the unifying feature of all RCLs will be viral particles containing RT. We test for RT after serial passage of culture supernatants on permissive human cells. We established the passage parameters of the EIAV RCL assay with reference to the well-characterized RCR assay control, 4070A amphotropic MLV. This was a valid approach because we demonstrated comparability between EIAV and MLV in two assays. First, wild-type EIAV and MLV replication kinetics were similar in equine cells. Secondly, the rates of virus like particle (VLP) production from noninfectious EIAV vectors expressing Gag-Pol were comparable to infectious MLV in human cells. In mixing experiments we demonstrated that EIAV vector preparations did not compete with MLV replication, nor was transduction by a small amount of appropriately pseudotyped EIAV or MLV vector inhibited. The assay is highly sensitive, reproducible and robust, it uses a validated positive control, MLV 4070A, and it can be conducted at a contract research organization to the standards of GLP and using the same general procedures and biosafety environment as used for MLV RCR assays.
Results

Design and assay of minimal EIAV based vector systems
The structure of wild-type EIAV is shown in Figure 1a and the most highly engineered self-inactivating (SIN) vector vectors derived from EIAV are shown in Figure 1b . All of the coding regions have been removed from the transfer vector with the exception of a short region of Gag, which contains multiple point mutations to ensure that no Gag peptide is expressed. The genome has only 864 nucleotides of the original approximately 8 kb remaining and the Rev/RRE (Rev Response Element) system is not required due to a short open reading frame (Neo) downstream of the packaging site (C). 21 The production components provided in trans are the GagPol gene and the VSV-G heterologous envelope glycoprotein. The codon optimization of Gag-Pol increases expression, removes the need for the Rev/RRE system, and removes the homology with the packaging site that is retained in the vector genome. 20 The system was designed to minimize the potential for generation of RCLs, as this would have to rely upon a complex series of unpredictable illegitimate recombinations.
All RCLs would by definition have to contain RT and it is possible to assay the level of RT using an F-PERT (fluorescent-product enhanced reverse transcriptase) assay. A number of retrovirus RTs perform similarly in this assay and it is highly quantitative and precise 22, 23 (and data not shown).
Comparing the replication kinetics of EIAV and MLV in equine and human cells
A prerequisite for successful assay development is to establish the likely replication kinetics of a putative RCL and to devise a positive control. EIAV does not replicate in human cells because there are two blocks to infection. Firstly, the EIAV envelope receptor is not present on human cells and secondly, Cyclin-T1 is required for Tat to function, but the human protein does not substitute for the equine protein due to sequence divergence. 24 One route would be to engineer the virus to be able to replicate in human cells, but we considered that this was not desirable, a decision supported by a recent guideline issued by the EMEA. 25 We therefore considered that another human cell tropic retrovirus might be used Figure 1 Schematic diagram showing the structure of (a) wild-type EIAV virus, and (b) the three components of the minimal EIAV vector system. The three regions of homology between the components are marked by the dotted lines. The vector genome component has multiple ATTG mutations preventing expression of Gag peptide sequences within the packaging signal (C) region. The Gag-Pol component is codonoptimized, but maintains homology with EIAV in the Gag-Pol overlap region to maintain the correct balance between the structural (Gag) and enzyme (Pol) polypeptides. A heterologous envelope glycoprotein, such as VSV-G, is used.
RCL assay for EIAV vectors J Miskin et al as a surrogate positive control for EIAV. One possible solution was to use the 4070A amphotropic MLV, as it is currently used as a positive control for RCR assays. To determine whether MLV was suitable as a control we compared the replication kinetics of MLV with EIAV in equine dermal (ED) cells, human cells (HEK293) and human cells containing the equine Cyclin-T1 gene (HEK293eCT1).
We identified the minimal dose of MLV and EIAV virus stocks that would give a detectable infection of HEK293 cells or ED cells, respectively. The F-PERT titre of the MLV and EIAV minimal virus dose was within 10-fold, suggesting that similar amounts of EIAV and MLV particles were being used to establish the infections (data not shown). Following infection, the culture supernatants were harvested prior to passage at days 2, 5, 8, 13 and 20 and the cultures were maintained for a total of 28 days. The supernatants were assayed for viral particles using the F-PERT assay (Figure 2) . MLV 4070A developed a productive infection in all three cell lines, but EIAV only productively infected ED cells. In ED cells, the viral production kinetics of EIAV were very similar to that of MLV 4070A, both in terms of the rate of particle production and the steady-state maximum levels. The rate of particle production was likely a product of the rate of particle release from individual cells, the growth rate of the cells, and the removal of pre-existing virus during each passage. ED cells divided more slowly than HEK293 cells, so the rate of increase of infected cells producing particles in a given culture would be lower for ED cells. This observation may at least partially explain why MLV replication appeared slightly slower in ED cells than in HEK293 cells. The lack of a productive EIAV infection in human cells, even when engineered to express the equine Cyclin-T1 gene, reflects the barrier to cell entry. 26 Based on these observations, there is no a priori reason to suppose that an EIAV derived RCL would emerge unusually slowly. The data indicate that MLV could be used to model the replication of EIAV in ED cells. However, we also needed to test these conclusions about the comparability of MLV and EIAV by modelling the replication kinetics of EIAV in human cells.
Characterization of the rates of EIAV and MLV VLP production in human cells
We considered that any RCL would have to generate VLPs and therefore a comparison of the rates of particle production between MLV and EIAV would indicate the likely comparability of a productive infection in human cells. In order to measure the rate of VLP production by EIAV, we developed a series of replication defective vectors that we refer to as EMOB (EIAV MOBilisable) vectors. The different EMOB vectors were designed to test the effect on VLP production of making the virus increasingly disabled. We did this to try to gauge the likely potency of any putative RCL. A schematic diagram of EMOB vectors 1-8, indicating the presence (+) or absence (À) of the accessory region and the configuration of 3 0 LTR, which will become both LTRs in the provirus, is shown in Figure 3a .
All of the EMOB vectors contain the codon optimized Gag-Pol gene to provide the VLPs and enzymes (RT and integrase), as would occur in any putative RCL derived from the minimal vector system. The packaging site (C) is the same as in the minimal vector system (see Figure  1) . In some cases, a region of EIAV that allows expression of Tat, Rev and S2, and also contains the RRE that collectively we refer to as the 'accessory region' was retained (EMOB-1, EMOB-2, EMOB-4, EMOB-8), while the remainder had this region deleted to mimic the situation of an entity derived from the minimal vector production system. EMOB-2 was equivalent to an Env gene defective EIAV, and EMOB-6 was considered the closest to the minimal vector system. Equivalent F-PERT units of each EMOB vector preparation were inoculated onto ED, HEK293 or HEK293eCT1 cells at an m.o.i. of 10, alongside a pONY8.0G control for the transfer of pre-existing vector-associated RT activity. At 6 h after transduction, the majority of pre-existing RT activity was removed by passaging the target cells into fresh tissue culture plates. It was possible to discriminate between the pre-existing and de novo synthesized RT by measuring the baseline RT activity in each culture immediately after transfer to fresh plates. The efficiency of integration onto target cells was determined by a Q-PCR based integration assay and was shown to be similar for all EMOB constructs except EMOB-4 and EMOB-5, which were 10-fold lower indicating that this particular heterologous configuration was highly defective (data not shown).
The number of VLPs in the culture supernatant was estimated using the F-PERT assay by reference to a standard, and the F-PERT-predicted titre values are plotted against time in the three cell lines (Figure 3b-d ).
In Figure 3b particle production from ED cells is shown. De novo synthesized VLPs were marginally detected after only 15 h, and very clearly detected after 41 h from EMOB-1, EMOB-2 and MLV 4070A, reflecting the time for integration, expression and release of particles to detectable levels. The rate of increase and the steadystate level of MLV-derived VLPs were very similar to EMOB-2. These data mimic the findings in ED cells where wild-type infectious EIAV was similar to MLV, and consequently show that EMOB-2 is a valid surrogate for EIAV. Substitution of the EIAV U3 region by MLV U3 (EMOB-1) resulted in a longer lag phase, a slower rate of particle production and about 20% of the final VLP yield Figure 2 Comparison of the replication rates of MLV 4070A and wild-type EIAV in equine and human cell lines. The rate of particle production and subsequent release into supernatant fluid was measured using the F-PERT assay over a passage period of 28 days. Cell lines were equine dermal (ED), HEK293 (293), and HEK293 cells engineered to express equine Cyclin-T1 (293-eCT1). Cells were infected with minimal infectious doses of MLV (MLV 4070A), or wild-type EIAV (EIAV). Control cells were mock-infected (Mock).
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J Miskin et al of EMOB-2 or MLV. Substitution of the EIAV U3 with CMV enhancer reduced VLP production to undetectable levels. Interestingly, the EMOB vectors lacking the 'accessory region' did not produce any detectable VLPs in equine cells over the 6-day period. In HEK293 cells (Figure 3c ), MLV released VLPs with similar kinetics to those in ED cells, again mimicking the infection kinetics ( Figure 2 ). However in HEK293 cells, the only EMOB vector that released detectable VLPs was EMOB-1, albeit at a low level, presumably because the MLV U3 allowed some degree of Cyclin-T1-independent expression. In contrast, EMOB-7, the 'accessory region'-deleted version of EMOB-1, did not produce any particles. In the HEK293eCT1 cells (Figure 3d ), the rate of VLP release by EMOB-2 was the same as that for MLV and the steadystate yield of EMOB-2 was within 70% of MLV. EMOB-1 also produced VLPs but at a slightly lower rate comparable with the kinetics in ED cells, but more rapidly than was observed in HEK293 cells, presumably reflecting the activity of the Tat/TAR system with equine Cyclin-T1. The steady state of EMOB-1 VLPs was 30 or 45% of the corresponding MLV and EMOB-2 cultures, respectively. No other EMOB vector produced detectable particles. These data show that any version of EIAV able to replicate in human cells and that was similar to the wild-type configuration would have a similar replication potential to MLV in human cells. However, they also indicate that unless recombination led to the acquisition of an enhancer/promoter and the 'accessory region' (or a substitute), there would be no VLP production in human cells. Furthermore, the acquisition of a functional Cyclinindependent enhancer appears unlikely because two specifically engineered derivatives that were designed to maintain the integrity of the U3 structure and the R regions, while containing the 'accessory region' were heavily compromised (EMOB-1 and EMOB-4). Based on these observations, it can be concluded that generation of an RCL would require acquisition of Gag-Pol, an LTR with a functional enhancer and promoter, an envelope glycoprotein, additional sequences that augment transcription and/or RNA stability, and other features from 0 -LTR that will be copied to the 5 0 -end during reverse transcription and integration is shown. The rate of particle production and subsequent release into supernatant fluid from (b) ED cells, (c) 293 cells, and (d) 293-eCT1 cells was measured using the F-PERT assay over a period of 137 h, allowing a comparison of the particle production rates of MLV 4070A and EIAV 'mobilizable elements' in equine and human cell lines. Cells were treated with equal amounts of RT activity of the indicated virus (MLV 4070A), 'mobilizable element' (EMOB-1 to EMOB-8), control (pONY8.0G or EMOB-2 [-VSV-G]), or untreated (Mock).
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These data also support the conclusion that EIAV and MLV have similar replication potential in equine cells. Taken together, the data indicate that starting either from a minimal infectious dose of virus (Figure 2) , or from an m.o.i. of 10 using EMOB vector particles (Figure 3) , then virus or VLP production can be readily detected by the F-PERT assay by 4 days. Collectively, the data indicate that MLV 4070A was a strong candidate for the positive control virus to be used in RCL assays for release testing of EIAV vector products.
Design and performance of the RCL assay
Retroviral vectors can potentially interfere with the replication of another retrovirus, and this has been demonstrated for the murine retroviruses. 27 We performed mixing experiments to investigate competition between EIAV vectors and either the MLV 4070A positive control or a VSV-G-pseudotyped EIAV LacZ vector to mimic a minimal infectious dose of an EIAV-derived RCL. No competition was observed (see supplementary information). On the basis of the assessments of EIAV infection and particle production characteristics and the competition studies, we devised an RCL assay that we anticipated would detect an RCL with wild-type replication kinetics by 10-14 days. To ensure that vectorassociated RT activity was reduced to baseline so that it could not be mistaken for an RCL in the F-PERT end point assay, the tissue culture phase of the assay is performed over a 4 to 5 week period. We used MLV 4070A as a positive control for the reasons described herein. MLV 4070A has other advantages as a positive control because it is already a well-characterized positive control for the detection of RCRs, and is available from the ATCC. HEK293 cells were chosen as an appropriate test cell line because they are the parental line for the production cells which are HEK293T, they are permissive for human cell tropic retroviral and lentiviral vectors and, as we show above, for EIAV VLP production from defective viral genomes.
Current US FDA recommendations suggest that 5% of the clinical lot material is tested for replication competent viruses (the clinical lot assay), and up to 10 8 end-ofproduction cells (EOPC) are also tested (the cocultivation assay). 28 To test 5% of the product, and to keep the assay on a manageable scale, studies were performed to determine the maximum vector m.o.i. that could be used without having a detrimental effect on the growth rate of the HEK293 amplification cells. It was found that an m.o.i. of up to 50 could be used without affecting the transduction by control MLV or EIAV vectors, or replication of the MLV 4070A positive control virus in pilot-scale RCL assays (data not shown). These data allowed us to develop a sampling and amplification protocol for the RCL assays. The vector and EOPC material used was obtained from three different development production runs of ProSavin s EIAV vector. In order to test 5% of an appropriate manufacturing scale 
The F-PERT analysis shown in Figure 4a and b demonstrated that the MLV positive control virus reached steady state at passage 3/4, and followed the same pattern when spiked into the test article. Due to the high stability of EIAV RT activity in culture supernatant, it was necessary to perform at least six passages in order to reduce the vector-derived RT activity to baseline; the test article and negative control traces were indistinguishable after five or six passages. To ensure that RT activity was reduced to baseline in all assays and for all potential vectors, the assay was extended beyond passage 6 to PP8/PP9, which is a total of approximately 4 to 5 weeks after inoculation. In addition to the F-PERT analysis of unconcentrated samples from all time points, concentrated supernatant fluid samples from the final passage were subjected to F-PERT analysis in a GLPcompliant assay, as will ultimately be performed for vector lot release testing (data not shown). The end point F-PERT testing showed that RT activity was usually undetected in the 'test article' flasks or the 'negative control' flask, but was detected in the 'positive control' and 'spike' flasks due to replication of the MLV 4070A positive control virus.
Occasionally, during the GLP end point F-PERT analysis, test article flasks had Ct values lower than the designated cutoff value for a positive result (Ct value of 35.59). It is known that the high sensitivity of the F-PERT assay means that occasionally the assay can lead to false positive results, either due to endogenous retroviral RT activity released from the tissue culture cells under stress, or due to cellular polymerases that possess RT-like activity. 23 In such cases, filtered supernatant fluid from the final passage was exposed to fresh HEK293 amplification cells, followed by a two additional passages in order to remove nonreplicating RT activity, and positive and negative controls were included. All cases where RT activity was detected in the end point F-PERT analysis were attributed to non-replicating RT, as the RT activity was not transferred to fresh amplification cells during the additional testing. None of the minimal EIAV vector preparations tested thus far have contained RCL.
One of the samples shown to be a false positive result in the end point analysis was further investigated (test article A from cocultivation RCL assay, contract research organization (CRO) accession number 1040512). This false positive was identified both in the GLP-compliant RCL assay for EIAV vectors J Miskin et al end point F-PERT analysis, and also in the 'informational' analysis of all of the supernatant fluid samples over the course of the assay. The latter revealed RT activity that increased over the final five passages, as shown by a reduction in the Ct value from 36.4 (PP4) to 27.8 (PP9; see Figure 4c ). A number of further experiments were then conducted and the conclusion from these experiments was that the RT activity originated from a stably transfected population of EOPC (data not shown). Proof that the RT activity was derived from EOPCs was that the SV40 large T-antigen DNA sequence was present at a copy number consistent with HEK293T cells, and at the end of the assay only HEK293 cells and not HEK293T cells (or EOPCs) should have been present. A filtration step is incorporated after P2, specifically to eliminate EOPCs from the culture, and this result indicated that the filtration had failed in this case. This result clearly illustrated the exquisite sensitivity of the F-PERT assay to detect low levels of RT activity.
Discussion
We have devised a readily scaleable assay for RCLs in clinical scale preparations of a minimal EIAV-based vector. The assay has been validated on three independent pilot-scale manufacturing lots of a gene therapy vector, ProSavin s . Five percent of the clinical vector lot or 10 8 EOPCs are used to infect a test human cell line. The cells are serially passaged for up to 10 passages over a 4 to 5 week period, and the final culture supernatants are assayed using the F-PERT assay. 23 The cutoff point for a positive result in the F-PERT assay has been defined by trend analysis of data by the CRO, and through discussion with the regulatory authorities, as a Ct value of 35.69 or lower. A clinical lot is shown to be free of RCL if the Ct values for the concentrated final passage supernatants from all flasks of the test article are above the cutoff. The assay is considered valid if the MLV positive control and spike control Ct values are below the cutoff, and the negative control Ct value is above the cutoff, and considered invalid if any one of these criteria is not met. Any test article that falls below the cutoff and considered positive in the initial analysis is investigated by further passage of filtered culture supernatant. This assesses whether it is a false positive, or represents a RCL. The robust nature of the assay has been demonstrated by an in-process failure, where production cells were carried over into the amplification cell culture leading to a low level release of RT that increased with time as the test cells became increasingly contaminated. This was resolved by showing that the RT could not be propagated by the subsequent passage of filtered supernatants.
We consider that the number of passages is in excess of what would be required for RCL or MLV detection, as the positive control reaches a steady-state maximal level at passage 3/4. However, EIAV RT is very stable and persists for multiple passages, so longer passage times are required to prevent assay failure due to vector carryover. Our analysis of the replication kinetics of the EMOB vectors in equine and human cells indicates an RCL that was similar to EIAV (through its acquisition of a functional LTR (enhancer, promoter), an envelope glycoprotein, and other factors to enhance transcription and RNA stability/transport), would emerge at a similar time to MLV. The assay takes 4-5 weeks and this is manageable, but with every passage there is the potential for assay failure due to contamination or human error. We believe therefore that we have achieved the correct balance between pragmatism and maintenance RCL assay for EIAV vectors J Miskin et al of maximum sensitivity. The F-PERT assay is proving to be highly sensitive and reproducible as a means of detecting RT associated with retroviral entities, as has been previously described. 22, 23 The culture and amplification process defined by the RCL assay increases the amount of MLV 4070A to approximately three orders of magnitude above the detection limit of the F-PERT assay within the first three or four passages. Therefore, the assay would detect an RCL with highly attenuated replication characteristics, by its amplification above the detection limit at the end of the 4-to 5-week amplification period. For example, the 'accessory region'-positive replication-deficient vector, EMOB-1, showed an eightfold increase in particle number over the test period of 137 h in HEK293 cells. This equates to three population doublings in the test period, and consequently an approximate doubling time of 45 h. Based on these observations one can hypothesize that, given the ability to replicate rather than to just produce VLPs, even a severely attenuated virus would be above the limit of detection of the F-PERT assay at the end of the 4-5 week period. We have used a similar F-PERT-based assay for MLV RCRs to conduct release testing of manufactured lots of RD114-pseudotyped MetXia s , an MLV vector that is currently in clinical trials (unpublished data). We suggest that this approach is now sufficiently validated for it to be adopted as a generic assay for RCRs or RCLs, using the MLV 4070A reference standard that is already available from the ATCC.
The choice of positive control for RCL assays is challenging given that the latest incarnation of vectors are so different from their corresponding starting virus, and these may not naturally replicate in human cells. This has been tackled for HIV based vectors by use of an attenuated replication competent HIV-1 virus with HIV envelope, 29 or another attenuated HIV-1 virus that was transiently pseudotyped with VSV-G for the first round of infection, and subsequently amplified on an HIV-1 susceptible cell line. 30, 31 However, both these approaches rely on the amplification of RCL in a human cell that expresses the receptor for HIV-1 envelope. An alternative approach was to artificially generate novel HIV-1 viruses with the heterologous envelopes VSV-G or amphotropic Env. 32 This latter approach was interesting in that both viruses were infective in HEK293T cells, but had demonstrably different replication characteristics. Both, however, were easily detected by various methods specific to the vector system, with the proviso that several weeks should be allowed for the in vitro amplification of RCL prior to detection. Use of either attenuated HIV-1 or a novel HIV-1 entity would necessitate the use of conditions of high biological containment (BSL3, or above), which is potentially problematic for the transfer to a CRO. Both of the approaches described above are only directly relevant for RCL testing of HIV-1 vectors, and are also biased towards the use of VSV-G or amphotropic Env. One avenue we could have explored was to modify EIAV to change its tropism. We considered that this would be technically challenging requiring changes to the envelope and the Tat/TAR system in the context of multiple splicing. We also considered it undesirable to create a novel replicating EIAV-derived entity, as was recently stated by the EMEA. 25 We therefore took the alternative approach of evaluating an established positive control for its ability to model EIAV replication kinetics. This proved to be the case in a productive infection analysis in equine cells, and also in analysis of VLP production in human cells. The 4070A amphotropic virus is available from ATCC as a reference standard for RCR assays and can be used in any laboratory facility.
We chose to use HEK293 cells because of their robust culture and passage properties, the fact that they are widely available, and also that they are highly permissive for many retroviral and human lentiviral infections with a variety of envelopes (e.g. VSV-G, 4070A, RD114, GALV). Other groups have recently included HEK293-based cells in strategies to devise a RCL assay for HIV-1 vectors for similar reasons. 29, 32 In addition, as they are the parent of the production cells, it is highly likely that any RCL that can replicate in the production cells will also replicate in the test cells. We considered using equine cells, but as we did not pursue this option for multiple reasons. Firstly, we are especially interested in a human pathogen rather than one that can replicate in equine cells. Secondly, the minimal vector system is far removed from the original wild-type equine vector. Thirdly, equine cells are poorly characterized and not validated. Finally, and most importantly, the reason EIAV does not replicate in human cells is two-fold; the lack of an EIAV Env receptor on human cells, 26 and the absence of a functional Cyclin-T1 to cooperate with EIAV Tat/ TAR. 24 As neither EIAV Tat nor EIAV Env constitute part of the minimal EIAV vector system, there is no scientific rationale that would argue for the use of equine cells for RCL testing.
The assay that we have developed should be applicable to any lentiviral vector provided that preliminary experiments confirm a number of issues of comparability: firstly that there is no vector competition, secondly that the vector is not toxic to the test cells at an m.o.i. which would allow for screening 5% of the clinical lot on a manageable scale, and thirdly that the replication kinetics in the test HEK293 cells of the appropriate replication competent virus, or a relevant substitute, were not substantially slower than MLV. Provided that the modelled replication kinetics would predict amplification of an RCL within the test period of 4-5 weeks, the assay would be directly applicable to the vector system. The opportunities for harmonizing this assay across all lentiviral vectors and creating generic reference standards should be beneficial to this rapidly developing and exciting area of gene therapy. vector and subjected to two rounds of limit dilute cloning. Clones were screened based on their ability to rescue EIAV particle production from EMOB-2, as measured by F-PERT.
Methods
Cell lines and viruses
Retroviral and lentiviral vectors
The HA-tagged full-length eCT1 cassette was RT-PCR amplified from ED cell RNA and cloned downstream of an internal CMV promoter in the retroviral (MoMLV) transfer vector, pTRAP2; vector was produced by transient transfection in HEK293T cells using the plasmids pHIT60 (MoMLV Gag/Pol expression plasmid) and pRV67 (VSV-G expression plasmid). The EIAV vector pONY8.0G has been described previously. 20 The EMOB vector series contained a number of common features: all ATG sequences located within the first 372 bp of the Gag ORF (region of the packaging signal [C]) were mutated to ATTG by inserting additional T nucleotides. The codon-optimized Gag-Pol cassette 20 was cloned directly downstream of the C site. Downstream of the Gag-Pol cassette, EMOB's 1, 2, 4 and 8 contained the accessory gene region, which has a 736 bp HindIII deletion within the Env coding region in order to prevent expression of EIAV Env, but contains the coding sequence for S2, the 2nd exon of Tat, the Rev coding region and the RRE. EMOB's 3, 5, 6 and 7 do not contain the accessory region. The 3 0 LTR in each of the EMOB vectors is as follows: (i) full-length EIAV LTR (EMOB-2, EMOB-3), (ii) SIN EIAV LTR (EMOB-6, EMOB-8), (iii) EIAV/MLV hybrid LTR (EMOB-1, EMOB-7) or (iv) hybrid CMV/EIAV LTR (EMOB-4, EMOB-5). A diagram of the EMOB vector series is shown in Figure 3 . EMOB vectors were produced by transient cotransfection of HEK293T cells with pRV67 (VSV-G). EMOB vectors without the accessory gene region (EMOB-3, 5, 6 and 7) included pESYNRev, a codon-optimized EIAV Rev expression construct.
ProSavin s vector genome is based on the vector genome construct shown in Figure 1b , into which was inserted a cassette containing (in order): Neo, an internal CMV promoter, three codon-optimized human genes involved in the biosynthesis of dopamine linked by internal ribosome entry sites (IRES; truncated tyrosine hydroxylase (tTH), aromatic amino acid dopa decarboxylase (AADC), GTP-cyclohydrolase I (GTP-CH1)), and the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). 33 
Product enhanced reverse transcriptase assay
For the GLP-compliant analysis of concentrated supernatant fluid samples conducted at a CRO, methods were as described. 23 For the 'informational' analysis of unconcentrated supernatant fluid samples, a modified F-PERT assay to that previously reported was used. 20, 22 Defining the minimal infectious dose of MLV 4070A in HEK293 cells MLV 4070A obtained from the ATCC had a titre determined on PG-4 cells of 1.5 Â 10 7 focus forming units per ml (FFU ml À1 ). 2 Â 10 5 HEK293 cells were seeded in six-well plates and infected with 10, 100, or 1000 FFU of MLV 4070A in the presence of 8 mg ml À1 polybrene.
Negative control cells were included. At 24 h after infection, cells were washed, trypsinized and washed again in order to remove pre-existing viral RT activity. Samples were taken immediately after re-seeding the cells, and after a further 120 h in culture. Samples were analysed for RT activity using the F-PERT assay. The number of wells that were positive for RT activity after 120 h for each infectious dose was determined. The results were used in conjunction with the Poisson distribution in order to determine the minimal infectious dose of MLV 4070A that would lead to a productive infection of HEK293 cells in 95% of cases. This was 80 FFU of MLV 4070A (data not shown).
Comparison of the replication kinetics of MLV 4070A and wild-type EIAV
The F-PERT assay was used to compare the RT activity of infectious EIAV or MLV 4070A. Three amounts of infectious EIAV were tested that contained equivalent RT units to 8, 80 or 800 FFU of MLV 4070A. 6.7 Â 10 5 HEK293, HEK293eCT1 or ED cells were seeded into 25 cm 2 flasks in a total culture volume of 5 ml. The following day, flasks were infected with MLV 4070A, or wild-type EIAV, with polybrene at 8 mg ml
À1
. Incubation was continued at 371C with 5% CO 2 . Uninfected cells were included as a control. A sample of cell-free supernatant fluid was taken immediately after infection, and the medium was changed 24 h postinfection. Each flask was passaged at 2, 5, 8, 13, 20 days postinfection as follows. Culture supernatant fluid was harvested and filtered through a 0.45 mm syringe filter unit, and samples were frozen at À801C. The cell monolayers were passaged as previously described using fresh 25 cm 2 flasks (1/6th of the HEK293 and HEK293eCT1 cells, or 1/3rd of the ED cells were transferred). The F-PERT assay was used to measure RT activity in each sample. The minimum ED-cell infectious dose of EIAV contained the same amount of RT activity as 800 FFU of MLV 4070A.
Comparison of the particle production kinetics from EIAV 'mobilizable elements' with MLV 4070A Wells of six-well plates were inoculated with 7 Â 10 4 cells (HEK293, HEK293eCT1, or ED cells) in complete medium. The following day, the culture supernatant fluid was removed and replaced with 0.6 ml of complete medium containing 5-7 Â 10 5 TU of the appropriate vector (based on F-PERT comparisons to the pONY8.0G reference standard; m.o.i.B10). At 6 h post-transduction, the cells were washed with PBS and trypsinized as before to remove the vector-associated RT activity. The cells were then transferred to a well of a six-well plate in a total volume of 2 ml, and incubated at 371C with 5% CO 2 . A minimal volume of cell-free culture supernatant fluid was collected at each of six time points postplating from 0-150 h (75 ml, to allow duplicate 25 ml samples to be frozen). The samples from each time course were analysed using the F-PERT assay as described above.
RCL assays
RCL assays and F-PERT testing were performed at a CRO (BioReliance Ltd, UK) under GLP-conditions, following protocols that are summarized below. The test articles used were generated from preclinical scale flasks (P0). Passages were continued in a similar fashion until a total of 10 passages were complete, and cell-free culture supernatant fluid samples were taken from the confluent flasks at each time-point for 'informational' analysis. After the final passage, cells were retained as viable stocks as a back-up in order to provide material for characterization of any positive signal detected using the F-PERT assay. Duplicate 14 ml samples (of 30 ml total) of the final cell culture supernatant fluid were collected from each 'test article' or control flask. For GLPcompliant F-PERT analysis, one of the duplicate samples was concentrated by ultracentrifugation, resuspended in particle disruption buffer to release RT activity, and subjected to analysis with the F-PERT quantitative RT assay. 23 The duplicate was retained as a back-up.
Cocultivation RCL assay
For the EOPC material, the producer cells from all of the culture vessels used for production were harvested after harvesting the vector preparation, and frozen as viable cell pellets containing 4 Â 10 7 cells. To initiate a cocultivation assay, vials of EOPC were thawed at 371C and cell viability was determined. Each of 10 'test article' flasks was inoculated with 1 Â 10 7 viable postproduction cells mixed with 1 Â 10 7 HEK293 test cells in a 150 cm 2 flask in the presence of 8 mg ml À1 polybrene. Control flasks were: (i) negative control with 1 Â 10 7 HEK293 cells mixed with 1 Â 10 7 HEK293T cells in a flask treated with polybrene alone; (ii) positive control was 1 Â 10 7 HEK293 cells mixed with 1 Â 10 7 HEK293T cells in a flask treated with 80 FFU of MLV 4070A and polybrene; (iii) spiked test article was identical to the test article flask, except 80 FFU of MLV 4070A was also included. Passages were continued as for the clinical lot RCL assay until a total of 10 passages were completed, except after the second passage, the culture supernatant fluid was harvested, filtered through a 0.45 mm filter, and used to inoculate a monolayer of HEK293 cells that were seeded the previous day with 1 Â 10 7 cells. Sampling and analysis was as for the clinical lot assay.
